These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 32595449)
1. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders. O'Connell EM; Lohoff FW Front Neurosci; 2020; 14():609. PubMed ID: 32595449 [TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system. Bell AS; Wagner J; Rosoff DB; Lohoff FW Neurosci Biobehav Rev; 2023 Jun; 149():105155. PubMed ID: 37019248 [TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease. Adorni MP; Ruscica M; Ferri N; Bernini F; Zimetti F Front Aging Neurosci; 2019; 11():120. PubMed ID: 31178716 [TBL] [Abstract][Full Text] [Related]
4. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
6. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281 [TBL] [Abstract][Full Text] [Related]
7. Function of proprotein convertase subtilisin/kexin type 9 and its role in central nervous system diseases: An update on clinical evidence. Zhu XB; Xu YY; Li LC; Sun JB; Wang YZ; Chen J; Wang C; Zhang S; Jin LY Drug Dev Res; 2024 Feb; 85(1):e22131. PubMed ID: 37943623 [TBL] [Abstract][Full Text] [Related]
8. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874 [TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332 [TBL] [Abstract][Full Text] [Related]
10. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways. Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations. Hopkins PN; Krempf M; Bruckert E; Donahue S; Yang F; Zhang Y; DiCioccio AT J Clin Lipidol; 2019; 13(6):970-978. PubMed ID: 31767518 [TBL] [Abstract][Full Text] [Related]
13. Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome. Wang M; Zhao D; Xu L; Guo W; Nie L; Lei Y; Long Y; Liu M; Wang Y; Zhang X; Zhang L; Li H; Zhang J; Yuan D; Yue L Metabolism; 2019 May; 94():47-58. PubMed ID: 30768966 [TBL] [Abstract][Full Text] [Related]